Premium
The biodistribution of [ 153 Gd]Gd‐labeled magnetic resonance contrast agents in a transgenic mouse model of renal failure differs greatly from control mice
Author(s) -
Wadas Thaddeus J.,
Sherman Christopher D.,
Miner Jeffrey H.,
Duncan James R.,
Anderson Carolyn J.
Publication year - 2010
Publication title -
magnetic resonance in medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.696
H-Index - 225
eISSN - 1522-2594
pISSN - 0740-3194
DOI - 10.1002/mrm.22553
Subject(s) - nephrogenic systemic fibrosis , gadolinium , biodistribution , in vivo , kidney , medicine , magnetic resonance imaging , nuclear medicine , chemistry , genetically modified mouse , mri contrast agent , pathology , endocrinology , transgene , in vitro , biology , biochemistry , radiology , microbiology and biotechnology , organic chemistry , gene
Nephrogenic systemic fibrosis occurs in renally impaired patients who have undergone contrast enhanced MR examination using intravenous gadolinium‐based contrast agents. The effect of impaired kidney function on the biodistribution of gadolinium‐based contrast agents was investigated using radiolabeled 153/Nat gadolinium‐DOTA, 153/Nat gadolinium‐DTPA, and 153/Nat gadolinium‐DTPA‐BMA in a transgenic mouse model of renal impairment. Renally impaired animals had more activity associated with their tissues than did control mice, and this increase varied according to the radiotracer injected. For example, after 7 days, renally impaired animals that received 153/Nat Gd‐DOTA had 3‐fold ( P < 0.037) more activity in their bone tissue, whereas renally impaired animals receiving 153/Nat Gd‐DTPA and 153/Nat Gd‐DTPA‐BMA had 8‐fold ( P < 0.0001) and 24‐fold ( P < 0.0001) more activity in their bone tissue, respectively. These findings demonstrate that renal impairment dramatically alters the tissue distribution of Gd 3+ ions in vivo, which are likely a critical factor in the development of nephrogenic systemic fibrosis. Magn Reson Med, 2010. © 2010 Wiley‐Liss, Inc.